Reviewing Zealand Pharma A/S (ZEAL)’s and Athersys Inc. (NASDAQ:ATHX)’s results

This is a contrast between Zealand Pharma A/S (NASDAQ:ZEAL) and Athersys Inc. (NASDAQ:ATHX) based on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zealand Pharma A/S N/A 0.00 N/A 3.00 5.18
Athersys Inc. 24.29M 8.81 24.28M -0.21 0.00

Demonstrates Zealand Pharma A/S and Athersys Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 represents Zealand Pharma A/S (NASDAQ:ZEAL) and Athersys Inc. (NASDAQ:ATHX)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Zealand Pharma A/S 0.00% 0% 0%
Athersys Inc. -99.96% -58.7% -44.6%

Analyst Ratings

The Recommendations and Ratings for Zealand Pharma A/S and Athersys Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Zealand Pharma A/S 0 0 0 0.00
Athersys Inc. 0 0 1 3.00

Competitively Athersys Inc. has a consensus price target of $8, with potential upside of 429.80%.

Insider & Institutional Ownership

The shares of both Zealand Pharma A/S and Athersys Inc. are owned by institutional investors at 9.28% and 23.7% respectively. Competitively, insiders own roughly 2.1% of Athersys Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zealand Pharma A/S 6.55% 7.93% 34.59% 9.24% -2.23% 33.89%
Athersys Inc. 1.97% -2.52% -19.69% -22.89% 15.67% 7.64%

For the past year Zealand Pharma A/S was more bullish than Athersys Inc.

Summary

Zealand Pharma A/S beats on 7 of the 11 factors Athersys Inc.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.